Overview: Liver and Kidney ProfileIntroduction: The Liver and Kidney Profile is a diagnostic tool designed to screen liver and kidney function using serum and urine samples. Associated with conditions like hepatitis and chronic kidney disease, these disorders present with jaundice, edema, and severe complications if untreated, particularly in individuals with suspected organ dysfunction. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with spectrophotometry and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for organ function monitoring in clinical settings. This diagnostic falls under organ function monitoring and targets individuals with suspected liver or kidney disease, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.Other Names: Liver Kidney Pfl.FDA Status: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 1980s by clinical labs, this test advanced organ function screening.Purpose: The test screens for 23 parameters including total bilirubin to guide liver and kidney assessment, assess organ function, and inform treatment and prevention strategies.Test Parameters: 1. Total Bilirubin, 2. Direct Bilirubin, 3. AST, 4. ALT, 5. ALP, 6. Total Protein, 7. Albumin, 8. Globulin, 9. GGT, 10. Creatinine, 11. Urea, 12. eGFR, 13. Sodium, 14. Potassium, 15. Chloride, 16. Calcium, 17. Phosphorus, 18. Uric Acid, 19. Urine Protein, 20. Urine Creatinine, 21. Urine Albumin/Creatinine Ratio, 22. Urine Microalbumin, 23. Bicarbonate.Pretest Condition: Fasting 10-12 hours required; patients should report jaundice, edema, or recent organ symptoms.Specimen: 3 mL serum in 1 SST, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.Sample Stability at Room Temperature: 8 hours (Serum), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 7 days (Serum, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.Medical History: Patients should provide details on jaundice, edema, prior organ reactions, or family history of liver/kidney disease, as well as any recent trauma or treatments.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated organ disease including failure, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test involves sample processing using spectrophotometry and microscopy and interpret results within 1-2 days using provided controls.Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.Clinical Significance: Abnormal results indicate possible liver or kidney disease, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.Specialist Consultation: General practitioners or specialists in hepatology or nephrology should be consulted for case management, treatment planning, and coordination with health programs.Additional Supporting Tests: Imaging or biopsy for confirmation.Test Limitations: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.References: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Hepatology 2024, Chemistry 2025.